Equillium Inc Dossier - Source-backed chat

Equillium Inc

EQNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.52

Intrinsic Value $1.50median of 2 methodsbased on filings through 30 Jun 2026

Market Price $1.54Price as of 1 Oct 2026

Near fair valueIntrinsic value is 3% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $97.6M

Enterprise Value $41.2M

Shares Outstanding 63.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Equillium, Inc. is a clinical-stage biotechnology company that has successfully pivoted its strategic focus toward its novel, non-immunosuppressive Aryl Hydrocarbon Receptor (AhR) platform, led by EQ504. Following a transformative $35 million private placement in March 2026, the company has bolstered its cash position to $61.3 million, extending its operational runway into 2029. This robust balance sheet mitigates near-term financing risks and fully funds the upcoming Phase 1 proof-of-mechanism study for EQ504 in ulcerative colitis, scheduled to initiate in mid-2026. With a significantly narrowed net loss and a clean capital structure, Equillium presents an asymmetric risk-reward profile for investors seeking exposure to next-generation immunology therapeutics.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$8.56

High · most bullish analyst$20.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential clinical delays in the EQ504 Phase 1 trial or safety/tolerability signals that emerge during human testing. If the AhR mechanism fails to show clear target engagement or epithelial restoration in patients, the clinical timeline would be severely disrupted, forcing a reliance on earlier-stage assets and accelerating cash burn.

Base CaseCentral scenario

The base case assumes Equillium successfully initiates its Phase 1 proof-of-mechanism study for EQ504 in mid-2026 and delivers positive safety and biomarker data in early 2027. The $61.3 million cash runway successfully funds operations into 2029, allowing the company to advance EQ302 and its multi-cytokine platform without immediate dilutive equity pressure. Valuation aligns with the consensus analyst target as clinical milestones are met.

Bull CaseUpside scenario

Equillium's bullish thesis is driven by strong clinical and analyst momentum, particularly surrounding its lead candidate EQ504 (a novel Aryl Hydrocarbon Receptor modulator) which is progressing toward Phase 1 trials for ulcerative colitis. Additionally, positive Phase 2 topline data for itolizumab in moderate-to-severe ulcerative colitis, developed in partnership with Biocon Limited, provides significant clinical validation. The company's pipeline is further supported by multiple analyst upgrades and price target increases from major firms like Raymond James, Leerink, and Oppenheimer.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $61.3 million in cash as of Q1 2026, providing an operational runway into 2029.
Differentiated, non-immunosuppressive mechanism of action for lead asset EQ504, targeting both immune modulation and epithelial barrier repair.
Strategic pivot completed with the wind-down of legacy itolizumab programs, significantly reducing quarterly cash burn.
Strong institutional backing, highlighted by the $35 million financing led by RA Capital Management in March 2026.

Key Investment Risks

Early-stage clinical risk, as EQ504 is entering Phase 1 human testing and lacks established clinical efficacy data.
Potential for future shareholder dilution from outstanding pre-funded warrants, stock options, and the active ATM facility.
High competitive intensity in the autoimmune and inflammatory disease space, particularly in ulcerative colitis.

Thesis Invalidation Triggers

Failure to initiate the EQ504 Phase 1 study by the end of 2026.
Unfavorable safety or tolerability signals in the upcoming Phase 1 trial of EQ504.
Inability to demonstrate clear biomarker-driven target engagement or epithelial repair in early clinical readouts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.